Abstract
IntroductionDaratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and progression-free survival (PFS) while proving highly tolerable with minor increases in overall regimen toxicity. In non-transplant eligible patients daratumumab has been added in randomized studies to lenalidomide and dexamethasone (Rd) and bortezomib, melphalan and prednisolone (VMP) backbones, but not to the VCD regimen. Furthermore, the randomized studies excluded a significant proportion of patients with comorbidities so the benefit of daratumumab in a frail, elderly myeloma population remains untested.
Original language | English |
---|---|
Number of pages | 4 |
Journal | Blood |
Volume | 136 |
Issue number | Supplement 1 |
DOIs | |
Publication status | Published - 5 Nov 2020 |
Event | 62nd ASH Annual Meeting and Exposition - Duration: 5 Dec 2020 → 8 Dec 2020 Conference number: 62 |
Keywords
- Bortezomib
- Cyclophosphamide
- Dexamethasone
- VCD
- Daratumumab
- VCDD
- Myeloma
- untreated myeloma